Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPLE
NCT05748483Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of atogepant in migraine (2 arms), sponsored by AbbVie Inc. Primary endpoint: Percentage of Participants Who Discontinued Treatment Due to Treatment-Emergent Adverse Events at 24 weeks. Started Oct 2023; status: completed.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05748483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05748483.